Elizabeth Lucas

Elizabeth Lucas is a correspondent for Kaiser Health News, who specializes in data analysis and reporting.

News

Politics & Elections

Big Pharma Delivered Campaign Cash to Key Lawmakers With Surgical Precision

Campaign donations to members of Congress are only the tip of the iceberg of the industry's influence peddling.

By: Victoria Knight ,; Rachana Pradhan ,; Elizabeth Lucas ,; KaiserHealthNews

October 28, 2021

News

Environment & Health

Pandemic’s High Toll at the Texas Border Lays Bare Gaps in Health and Insurance

Health experts say Texas's lax COVID response and refusal to expand Medicaid contributed to the higher death rates.

By: Phil Galewitz ,; Elizabeth Lucas ,; René Kladzyk ,; KaiserHealthNews

June 23, 2021

News

Environment & Health

Pharma Cash Rolls Into Congress to Defend an Embattled Industry

Mitch McConnell, who is running for reelection, has seen an uptick in pharmaceutical industry donations this year.

By: Emmarie Huetteman ,; Jay Hancock ,; Elizabeth Lucas ,; KaiserHealthNews

August 28, 2019

News

Environment & Health

Big Pharma Gave Money to Patient Advocacy Groups Opposing Medicare Changes

About half of the groups representing patients have received funding from the pharmaceutical industry.

By: Sydney Lupkin ,; Elizabeth Lucas ,; Victoria Knight ,; KaiserHealthNews

March 8, 2019

Environment & Health

How a Drug Company Under Pressure for High Prices Ratchets Up Political Activity

As scrutiny of its soaring insulin prices escalated and drove its stock down, the pharma giant Novo Nordisk aggressively ratcheted up spending to spread its influence in Washington.

By: Jay Hancock &; Elizabeth Lucas ,; KaiserHealthNews

May 2, 2018

Environment & Health

Patient Advocacy Groups Take in Millions From Drugmakers. Is There a Payback?

A new database tallies money from Big Pharma to patient groups.

By: Emily Kopp ,; Sydney Lupkin ,; Elizabeth Lucas ,; KaiserHealthNews

April 13, 2018

News

Economy & Labor

Follow the Money: Drugmakers Deploy Political Cash as Prices and Anger Mount

Despite running into trouble this year, drugmaker, Mallinckrodtt, has been increasing its lobbying efforts in Congress.

By: Jay Hancock ,; Elizabeth Lucas ,; Sydney Lupkin ,; KaiserHealthNews

July 28, 2017

Sections

Latest

Trump Admin Could Kill Funding for Life-Saving Climate Resiliency Hubs

Report: Louisiana LNG Operators Set to Receive Over $21 Billion in Tax Breaks

Do the Resumed Gaza Ceasefire Talks Have a Chance of Finally Succeeding?

Wealth of the World’s Billionaires Has More Than Doubled Over the Past Decade

More

Elizabeth Lucas

Menu